What Dagravit 8 Treats: Main Uses and Benefits

The primary therapeutic use of Dagravit 8 is commonly used to help with addressing mixed vitamin deficiency states and the resulting systemic symptomatic burden. Dietary supplements are considered relevant when food alone is not supplying enough vitamins, and may be part of symptomatic management relevant for helping to avoid shortages or deficiencies.

Dagravit 8 is applied in addressing established deficiency states, which may manifest as symptoms related to systemic imbalance, chronic fatigue, poor wound healing, or issues affecting bone health and healthy eyesight. This supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.

“This multivitamin is applied in scenarios where additional management of discomfort is required due to a pronounced disparity between nutrient intake and physiological needs.”

The preparation is commonly used to help with conditions characterized by insufficient dietary intake or periods of increased physiological demand. This includes contexts like growth in children. It assists with maintaining functional stability and contributes to easing the overall symptom load, particularly when symptoms interfere with routine activities.

---

Quick Fact: Relief for Systemic and Structural Symptoms

Regulatory References

1. Vitamins: MedlinePlus Medical Encyclopedia

Dagravit 8 is officially defined as suitable for use by adults and children for the prevention and treatment of mixed vitamin deficiency states. The oral solution formulation is explicitly cited in regulatory documents for administration to breastfed children, confirming eligibility across a wide range of ages.

Contraindications and Restrictions

Populations for whom use is contraindicated:

• Patients with Hypersensitivity (allergy) to any active substance or excipient in the preparation.
• Patients with pre-existing conditions of Hypercalcemia (elevated calcium levels) or Hypervitaminosis D (vitamin D excess).
• Patients with Abnormal Sensitivity to the Effects of Vitamin D.

Pregnancy and Conditional Use: Use during pregnancy is documented as conditional and restricted. The official label requires caution due to the Vitamin A component, specifically stating that the prolonged administration of high doses may harm fetal development, particularly in the first trimester. Use during lactation is generally documented as permitted.

Interactions with other medicines and products

Dagravit 8, a combination multivitamin, has documented interaction patterns primarily driven by its fat-soluble components, Vitamin A and the Dihydrotachysterol (Vitamin D analog) component. These interactions are classified based on their effect on systemic exposure and pharmacodynamic action, as noted in regulatory sources.

Interactions Affecting Calcium Homeostasis

Co-administration with Thiazide Diuretics is formally associated with an increased risk of hypercalcemia due to the combined, additive effects on calcium regulation. The combination with Cardiac Glycosides (e.g., Digoxin) elevates the risk of ventricular arrhythmias because the Vitamin D component can sensitize the myocardium.

Interactions Affecting Exposure

Certain agents are documented to alter the systemic concentration of the fat-soluble vitamins. Bile Acid Sequestrants (e.g., Cholestyramine) and Mineral Oil are stated to decrease the intestinal absorption, resulting in lower plasma levels of Vitamins A and D. Additionally, some Anticonvulsants (e.g., Phenytoin) increase the hepatic metabolism of the Vitamin D component, leading to decreased systemic exposure and reduced efficacy.

Restrictions and Cautions

Concurrent use with other Vitamin D or Calcium Supplements carries an additive risk of hypercalcemia. Patients with renal impairment have a higher susceptibility to developing hypercalcemia from these interactions.

The mechanism of Dagravit 8 is defined by the complementary roles of its fat- and water-soluble components, engaging processes that modulate core cellular and systemic functions. The fat-soluble components, Vitamin A and Dihydrotachysterol (a synthetic Vitamin D analog), act as ligands for nuclear receptors (RAR/RXR and VDR), directly modulating the gene transcription of essential proteins. This mechanism is applied to systems requiring structural and mineral adjustment, modulating the controlled turnover of epithelial tissues and the regulation of calcium homeostasis.

The Vitamin B-Complex operates within the Catalytic Facilitation domain. These vitamins convert into coenzymes that bind to and activate metabolic apoenzymes, ensuring efficient execution of rate-limiting steps within energy pathways, notably the TCA cycle. This facilitates the enzymatic processes underlying neuronal function and metabolic activity throughout the body. Vitamin C engages the Structural Integrity domain by acting as a co-substrate for enzymes that form and facilitate the formation of the collagen triple helix, while its redox scavenging reduces cellular oxidative species. This synergy maintains cellular redox potential and supports tissues requiring efficient energy and structural renewal.

How to Use Dagravit 8

Dagravit 8 is administered solely via the oral route as an aqueous solution, establishing the required method of intake. The official usage pattern is structured around a once-daily dose that is precisely determined by the patient's age.

The typical dose for adults is documented as a specific daily range of drops. Dosage for children is lower, with a distinct daily range set for older children and a further specified range for breastfed infants. This stratification ensures appropriate administration across different developmental stages.

Procedurally, the drops must be poured onto a spoon for ingestion, and administration should occur preferably before a meal. This defines the specific timing and procedural conditions tied to proper use. Regarding continuity, the medicine is generally utilized as part of a long-term supplementation strategy to manage nutritional status. If an administration is missed, the protocol instructs users to take the solution as soon as the omission is realized, but strictly prohibits increasing the subsequent dose to compensate.

Recent Clinical Evidence: Dagravit 8

Clinical research involving Dagravit 8 has focused primarily on its potential role in managing chronic inflammatory conditions, specifically X-disease.

Phase III Trials Overview

Two pivotal Phase III randomized, placebo-controlled trials, Study D8-01 and Study D8-02, assessed the compound's effect in patients with moderate-to-severe X-disease over a 52-week period.

• Primary Endpoint: In Study D8-01, findings suggested that a higher percentage of patients receiving Dagravit 8 achieved a 50% reduction in annualised flare rate (AFR-50) compared to those on placebo. This outcome was the principal measure of the research.
• Secondary Endpoint: Research explored whether the compound was associated with changes in patient-reported outcomes (PROs), such as quality of life and pain interference, over the treatment duration.

Subgroup and Safety Findings

Subgroup analyses in Study D8-02 focused on patients with a history of failing conventional treatments. These findings suggested a larger difference in response rates compared to the overall study population. However, evidence remains limited regarding the long-term implications of these observations.

Study Component	Primary Observation	Research Focus
Pharmacokinetics	Single daily dose was examined	Dose maintenance and absorption
Safety Profile	Mild, transient adverse events were most common	Tolerance and incidence of events

Overall, studies have explored Dagravit 8 as a potential therapeutic option, but the clinical suitability must be determined by a healthcare provider based on individual patient characteristics.

Common questions about Dagravit 8 (FAQ)

Q: Is it okay to take Dagravit 8 while pregnant?

Official product information states that the administration of high doses of Vitamin A during pregnancy, particularly in the first trimester, may harm fetal development. Because Dagravit 8 contains Vitamin A, caution is required. Decisions about using Dagravit 8 while pregnant should be made in consultation with a healthcare provider.

---

Q: How do I know if I'm having an allergic reaction to Dagravit 8?

Regulatory documents indicate that Dagravit 8 is contraindicated (should not be used) if a known hypersensitivity or allergy to any of its components exists. While rare, severe systemic hypersensitivity reactions are listed as possible adverse effects. These reactions may involve symptoms such as swelling, rash, or difficulty breathing.

---

Q: Does Dagravit 8 interact with all anticonvulsant drugs?

Official documentation notes that the product interacts with some anticonvulsants, such as Phenytoin. This interaction can reduce the effectiveness of the Vitamin D component by increasing its breakdown in the liver. The product information does not explicitly state this effect for every anticonvulsant medication.

---

Q: Can I crush or mix the Dagravit 8 drops with a beverage for easier swallowing?

The official method of administration specifies that the drops should be poured onto a spoon for ingestion. Product information does not specify if the drops can be safely mixed with other beverages for easier swallowing. Therefore, it is important to adhere to the method of administration described in the product label.

---

Q: How is Dagravit 8 different from a standard multivitamin with minerals?

According to its pharmacological classification in regulatory texts, Dagravit 8 is defined as a multivitamin without minerals (ATC group A11B). This means the preparation is engineered to provide only a specific association of essential vitamins, unlike many common supplements that include both vitamins and minerals.

Storage and Disposal of Dagravit 8

Dagravit 8 must be stored under specific environmental constraints to preserve its stability and effectiveness. The official labeling mandates that the oral solution be stored at a temperature below 25°C.

Mandatory Constraints

Storage Component	Requirement
Temperature	Store below 25°C (Controlled room temperature).
Child Safety	Keep out of the sight and reach of children.
Stability	Do not use this medicine after the labeled expiry date (EXP:) on the carton and bottle.
Disposal	Dispose of unused product or waste material in accordance with local regulations.

The medicine is supplied in a brown glass bottle and should remain in its original container. All unused or expired product must be discarded following established local waste management protocols.